A Houston biotech company closed its initial public offering at the start of 2023 with plans to advance clinical trial development.
Coya Therapeutics is set to take $13 million in net proceeds following the closing of its IPO on Jan. 4. The offering included over 3 million shares of its common stock and accompanying warrants to purchase up to 1.5 million shares of common stock, priced together at $5.
The company will trade on the Nasdaq Common Market under the symbol COYA.
Coya’s stock…
